A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Status: Recruiting
Location: See all (54) locations...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 90
Healthy Volunteers: f
View:
• Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.
Locations
United States
Alabama
Local Institution - 0002
COMPLETED
Birmingham
Florida
Local Institution - 0003
COMPLETED
Miami
Georgia
Local Institution - 0014
WITHDRAWN
Atlanta
Local Institution - 0048
WITHDRAWN
Atlanta
Illinois
Local Institution - 0004
COMPLETED
Chicago
Local Institution - 0005
COMPLETED
Hazel Crest
Indiana
Local Institution - 0029
COMPLETED
Indianapolis
Local Institution - 0045
WITHDRAWN
Indianapolis
Missouri
Local Institution - 0028
COMPLETED
Saint Louis
Local Institution - 0043
WITHDRAWN
Saint Louis
New York
Local Institution - 0008
COMPLETED
New York
Oklahoma
Local Institution - 0041
WITHDRAWN
Oklahoma City
South Oklahoma Heart Research
RECRUITING
Oklahoma City
Tennessee
Local Institution - 0001
COMPLETED
Tullahoma
Texas
Local Institution - 0036
COMPLETED
Dallas
Local Institution - 0015
COMPLETED
Houston
Local Institution - 0051
WITHDRAWN
Houston
Other Locations
Argentina
Local Institution - 0053
NOT_YET_RECRUITING
Córdoba
Local Institution - 0054
NOT_YET_RECRUITING
General San Martín
Canada
Hamilton General Hospital
RECRUITING
Hamilton
Local Institution - 0011
WITHDRAWN
Montreal
Local Institution - 0030
WITHDRAWN
Toronto
Local Institution - 0037
COMPLETED
Toronto
Local Institution - 0040
WITHDRAWN
Toronto
Local Institution - 0035
WITHDRAWN
Trois-rivieres
Italy
Local Institution - 0009
COMPLETED
Bergamo
Local Institution - 0027
WITHDRAWN
Foggia
Local Institution - 0038
NOT_YET_RECRUITING
Foggia
Local Institution - 0052
WITHDRAWN
Massa
Local Institution - 0023
WITHDRAWN
Milano
Local Institution - 0033
WITHDRAWN
Milano
Local Institution - 0019
COMPLETED
Napoli
Local Institution - 0017
COMPLETED
Pisa
IRCCS Policlinico San Donato
RECRUITING
San Donato Milanese
Local Institution - 0050
WITHDRAWN
San Donato Milanese
Poland
Local Institution - 0031
COMPLETED
Bialystok
Local Institution - 0044
WITHDRAWN
Bialystok
Local Institution - 0006
WITHDRAWN
Krakow
Clinical Trials UMED Sp. z o.o.
RECRUITING
Lódz
Local Institution - 0020
WITHDRAWN
Lublin
Local Institution - 0049
WITHDRAWN
Lublin
Local Institution - 0024
WITHDRAWN
Oswiecim
Spain
Hospital Universitario Virgen de La Arrixaca
RECRUITING
El Palmar
Local Institution - 0039
WITHDRAWN
El Palmar
Local Institution - 0012
COMPLETED
Hospitalet De Llobregat
Local Institution - 0026
COMPLETED
Madrid
Local Institution - 0034
WITHDRAWN
Madrid
Local Institution - 0025
COMPLETED
Majadahonda
Local Institution - 0047
WITHDRAWN
Majadahonda
Local Institution - 0032
COMPLETED
Malaga
Local Institution - 0042
WITHDRAWN
Malaga
Hospital Nuestra Señora de Valme
RECRUITING
Sevilla
Local Institution - 0046
WITHDRAWN
Sevilla
Local Institution - 0010
COMPLETED
Valencia
Contact Information
Primary
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2023-11-07
Estimated Completion Date: 2026-07-03
Participants
Target number of participants: 48
Treatments
Experimental: BMS-986435
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb